Patents Examined by Ilia I Ouspenski
-
Patent number: 12281165Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: February 22, 2022Date of Patent: April 22, 2025Assignee: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Patent number: 12281163Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.Type: GrantFiled: September 30, 2020Date of Patent: April 22, 2025Assignee: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD.Inventors: Ting Xu, Kangping Guo, Dong Yang, Pilin Wang, Yuhao Jin, Xiaoxiao Wang
-
Patent number: 12268903Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: April 8, 2025Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 12263358Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.Type: GrantFiled: March 1, 2022Date of Patent: April 1, 2025Assignee: DEKA BIOSCIENCES, INC.Inventor: John Mumm
-
Patent number: 12257286Abstract: This document relates to methods and materials involved in treating mammals having a cancer (e.g., a cancer having one or more CD19 positive extracellular vesicles (EVs) and/or one or more small EVs in the tumor microenvironment). For example, methods of treating a mammal having a blood cancer including one or more CD19 positive EVs and/or one or more small EVs in the blood by administering one or more cancer immunotherapies (e.g., one or more chimeric antigen receptor (CAR) T-cell therapies) to the mammal are provided.Type: GrantFiled: October 31, 2019Date of Patent: March 25, 2025Assignee: Mayo Foundation for Medical Education and ResearchInventors: Saad J. Kenderian, Neil E. Kay, Michelle J. Cox, Fabrice Lucien-Matteoni
-
Patent number: 12246025Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.Type: GrantFiled: March 20, 2019Date of Patent: March 11, 2025Assignee: Genmab A/SInventors: Reshma Abdulla Rangwala, Esther C. W. Breij, Sandra Verploegen, Oyewale O. Abidoye, Leonardo Viana Nicacio
-
Patent number: 12241061Abstract: Provided are a CAR library used to screen scFvs that can be functional in CAR-T cells, and an scFv manufacturing method in which the CAR library is used. A chimeric antigen receptor (CAR) library of the present invention includes nucleic acids coding for first CARs. Each of the first CARs includes a first antigen-binding domain, a first transmembrane domain, and a first intracellular signaling domain. The first antigen-binding domain includes a first single-chain antibody (scFv) to be screened for the ability to bind to a target antigen. The first scFv includes a first heavy-chain variable region and a first light-chain variable region. The first heavy-chain variable region and the first light-chain variable region meet a predetermined condition.Type: GrantFiled: February 4, 2020Date of Patent: March 4, 2025Assignee: National University Corporation Ehime UniversityInventors: Toshiki Ochi, Masaki Yasukawa, Hiroshi Fujiwara, Katsuto Takenaka
-
Patent number: 12234274Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.Type: GrantFiled: August 5, 2021Date of Patent: February 25, 2025Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, John Scholler, Avery D. Posey, Jr.
-
Patent number: 12227555Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.Type: GrantFiled: January 13, 2021Date of Patent: February 18, 2025Assignee: The Trustees of the University of PennsylvaniaInventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
-
Patent number: 12227552Abstract: Disclosed herein are cell signaling complexes such as chimeric cytokine complexes and uses thereof. In some embodiments, a chimeric cytokine complex comprises a protein cage polypeptide, a plurality of engineered Fc antibody domains bound to the protein cage polypeptide, and one or more cytokines linked to each of the plurality of engineered Fc antibody domains. Also disclosed are Fc-cytokine complexes and uses thereof. In some embodiments, an Fc-cytokine complex comprises an engineered Fc antibody domain and one or more cytokines linked to the engineered Fc antibody domain.Type: GrantFiled: May 31, 2024Date of Patent: February 18, 2025Assignee: Nanotein Technologies, Inc.Inventors: Curtis Daniel Hodge, Zachary Ibrahim Imam, Luke Garland Haines
-
Patent number: 12227557Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.Type: GrantFiled: February 22, 2022Date of Patent: February 18, 2025Assignees: OncoC4, Inc., Children's National Medical CenterInventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang
-
Patent number: 12221489Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.Type: GrantFiled: August 27, 2020Date of Patent: February 11, 2025Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Xingxing Zang, James P. Allison
-
Patent number: 12203098Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.Type: GrantFiled: June 30, 2023Date of Patent: January 21, 2025Assignee: FATE THERAPEUTICS, INC.Inventors: Bahram Valamehr, Tom Tong Lee, Martin Hosking, Eigen Peralta, Chia-Wei Chang
-
Patent number: 12187787Abstract: The present invention relates to in a monoclonal antibody produced by CpG-DNA, or a functional fragment thereof, the monoclonal antibody, or functional fragment thereof, characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences a heavy chain comprising a complementarity determining region 1 (CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6 and a use of the same.Type: GrantFiled: February 26, 2019Date of Patent: January 7, 2025Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION, HALLYM UNIVERSITYInventors: Hyung Joo Kwon, Te Ha Kim, Dong Bum Kim
-
Patent number: 12188938Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.Type: GrantFiled: March 18, 2021Date of Patent: January 7, 2025Assignee: JANSSEN PHARMACEUTICA NVInventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
-
Patent number: 12186332Abstract: The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.Type: GrantFiled: June 26, 2020Date of Patent: January 7, 2025Assignees: Stowers Institute for Medical Research, The Children's Mercy Hospital, University of KansasInventors: Linheng Li, John M. Perry, Fang Tao, Xi C. He, Anuradha Roy, Scott J. Weir, Tara Lin
-
Patent number: 12180275Abstract: The present invention relates to combinations comprising anti-progastrin (anti-hPG) monoclonal antibodies and immune checkpoint inhibitors, as well as pharmaceutical compositions comprising said combinations. Methods of treatment of cancer using said combinations are also provided.Type: GrantFiled: June 25, 2021Date of Patent: December 31, 2024Assignee: Progastrine et Cancers S.À R.L.Inventor: Alexandre Prieur
-
Patent number: 12174193Abstract: Disclosed are methods and agents for predicting responses to therapy. More particularly, the present disclosure relates to methods and agents for detecting different forms of Programmed Death Ligand-1 (PD-L1) in cancer cells, which are useful for detecting location of PD-L1 in a cellular compartment (e.g., nucleus, cytoplasm, cell membrane) of a cancer cell, for predicting the likelihood of response of a cancer cell to therapy including immunotherapy, for stratifying a cancer patient as a likely responder or non-responder to a therapy, for managing treatment of a cancer patient, and for predicting clinical outcomes.Type: GrantFiled: January 15, 2019Date of Patent: December 24, 2024Assignee: EPIAXIS THERAPEUTICS PTY LTDInventor: Sudha Rao
-
Patent number: 12173071Abstract: Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.Type: GrantFiled: August 29, 2019Date of Patent: December 24, 2024Assignee: Seattle Children's HospitalInventors: Adam Johnson, Michael C. Jensen
-
Patent number: 12162928Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.Type: GrantFiled: July 30, 2020Date of Patent: December 10, 2024Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S COLLEGE LONDONInventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines